Skip to content

JBIO JBIO Return on assets

Return on assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
17.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-17%-6.9pp
Vera Therapeutics logo
Vera TherapeuticsVERA
-59.9%+187pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-20%-5.8pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-71.1%-127pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-45%+18.8pp

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

Based on trailing twelve months.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's return on assets?
JBIO (JBIO) reported return on assets of -65.3% in Q1 2026.
How has JBIO's return on assets changed year-over-year?
JBIO's return on assets increased by 41.0% year-over-year, from -110.7% to -65.3%.
What is the long-term trend for JBIO's return on assets?
Over 4 years (2021 to 2025), JBIO's return on assets has grown at a 24.0% compound annual growth rate (CAGR), from -25.5% to -60.3%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.